EJNMMI Research最新文献

{"title":"Early detection and localization of recurrent prostate cancer using [Formula: see text]F-DCFPyL PET/CT in patients with low and ultra-low PSA levels.","authors":"Ida Sonni, Alexandra Gulpe, Nicholas G Nickols, Derace Schaffer, Louis Montagut, Gholam R Berenji, Matthew B Rettig","doi":"10.1186/s13550-026-01490-0","DOIUrl":"10.1186/s13550-026-01490-0","url":null,"abstract":"","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"16 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13407815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preclinical PET characterization of [⁶⁸Ga]Ga-EMP-100 for non-invasive assessment of c-Met in NSCLC.","authors":"Timofei Rusu, Anita Rodenas, Leo Capet, Alexandre Perrier, Jean-Pierre Pouget, Alexandre Pichard, Julien Calvani, Martine Antoine, Serban Morosan, Christophe Portal, Jacques Cadranel, Aurelie Prignon","doi":"10.1186/s13550-026-01483-z","DOIUrl":"10.1186/s13550-026-01483-z","url":null,"abstract":"<p><strong>Background: </strong>The c-Met receptor is a key therapeutic target in non-small cell lung cancer (NSCLC). Current methods for assessing c-Met level, are limited by biopsy sampling, which fails to account for spatio-temporal and intra-tumour heterogeneity. This study aims to evaluate the use of PET/CT imaging for non-invasive, full-body quantification of c-Met expression in different subtypes of NSCLC, encompassing both ADC and squamous cell carcinoma and compare it to MET gene alterations and IHC c-Met scoring.</p><p><strong>Results: </strong>[⁶⁸Ga]Ga-EMP-100, a PET radiotracer targeting c-Met, was radiolabelled and characterized. Cell-Derived Xenograft (CDX) models of NSCLC with different characteristics were developed and validated for PET/CT imaging using [⁶⁸Ga]Ga-EMP-100. Tumour uptake and heterogeneity were quantified and compared to c-Met expression determined by IHC (H-score using SP44 and EP1454Y antibodies) and MET gene amplification detected by FISH and NGS. Automated radiolabelling of [⁶⁸Ga]Ga-EMP-100 demonstrated a high radiochemical yield (RCY) and purity (RP). Pharmacokinetics studies revealed rapid excretion predominantly by the renal pathway. PET/CT imaging resulted in high contrast and enabled non-invasive classification of CDX models regarding c-Met receptor levels. The highest tumour uptake was observed in H1648 and EBC-1 models. Although MET gene alterations were not correlated with c-Met protein expression at the cell surface, a good correlation was found between SUVmax and c-Met expression, when using the EP1454Y antibody.</p><p><strong>Conclusion: </strong>PET/CT imaging using [⁶⁸Ga]Ga-EMP-100 successfully quantified c-Met expression in vivo, clearly adding up to conventional IHC and genetic methods. Our study adds novel comparative evidence across tumour histotypes, providing new insight into how tumour phenotype affects c-Met-targeted imaging. This radiotracer holds potential as a non-invasive tool for selecting patients for c-Met-targeted therapies and monitoring therapeutic response in NSCLC. Further clinical studies are warranted.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13672760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148548310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Head-to-head comparison of ^99mTc-MIP-1404 CZT SPECT/CT and ⁶⁸Ga/PSMA-11 PET/CT for primary staging of high-risk prostate cancer: a phase II study.","authors":"Aws Saudi, Malin Ståhlgren, Prab Takhar, Pernilla Norberg, Martin Holmbom, Julia Dahl, Mostafa Afshar, Isidro Albert-García, Jon Forsberg, Marcus Ressner, Mathias Elgland, Veronica Sanchez-Rodriguez, Firas Aljabery, Miguel Ochoa-Figueroa","doi":"10.1186/s13550-026-01479-9","DOIUrl":"10.1186/s13550-026-01479-9","url":null,"abstract":"<p><strong>Background: </strong>To evaluate whether ^99mTc-MIP-1404 CZT SPECT/CT is non-inferior to ⁶⁸Ga-PSMA-11 PET/CT for metastases detection in patients with newly diagnosed high risk prostate cancer (PCa). Patients with newly diagnosed high-risk PCa (age range 50-79 years, mean 66) underwent three imaging modalities: 99mTc-HDP CZT SPECT/CT, 68Ga-PSMA-11 PET/CE-CT (contrast-enhanced CT), and 99mTc-MIP-1404 CZT SPECT/CT. Metastatic involvement of lymph nodes (LN) and bones were recorded. Repeated-measures ANOVAs and post-hoc analyses were used to compare modality performance. Sensitivity and specificity for LN and skeletal lesions were calculated based on PET scans as the reference standard. 99mTc-MIP-1404 CZT SPECT/CT-based therapy decisions were compared to 68Ga-PSMA-11 PET/CT-based decisions.</p><p><strong>Results: </strong>Sensitivity of ^99mTc-MIP-1404 CZT SPECT/CT for metastasis detection at the patient level was 81% for LN metastasis and 85% for bone metastases, compared with 57% for bone metastases by ^99mTc-HDP CZT SPECT/CT. There were no false positive findings by ^99mTc-MIP-1404 CZT SPECT/CT; specificity was 100% compared to ⁶⁸Ga-PSMA-11 PET/CE-CT. At lesion level analysis, ^99mTc-MIP-1404 CZT SPECT/CT had significantly higher detection rate of LN metastases compared with CE-CT (p = 0.026), but a lower detection rate compared to ⁶⁸Ga-PSMA-11 PET/CE-CT (p = 0.003). Classification of metastasis burden into high volume metastasis (HVM) and low volume metastasis (LVM) was concordant in 85% of cases based on ^99mTc-MIP-1404 CZT SPECT/CT compared to ⁶⁸Ga-PSMA-11 PET/CE-CT, while conventional imaging agreed in 64% of cases. Therapy decisions based on ^99mTc-MIP-1404 CZT SPECT/CT were concordant with those based on ⁶⁸Ga-PSMA-11 PET/CE-CT in 91% (30/33) of patients.</p><p><strong>Conclusions: </strong>^99mTc-MIP-1404 CZT SPECT/CT demonstrates strong diagnostic capability for metastatic staging and therapy planning in newly diagnosed high-risk PCa, outperforming conventional imaging. While ⁶⁸Ga-PSMA-11 PET/CE-CT identified more additional lesions, concordance in treatment decisions remained high. Considering its broader accessibility, ^99mTc-MIP-1404 CZT SPECT/CT may represent a practical alternative for primary staging, especially in settings with limited PET/CT availability. The study was approved by the Swedish Ethical Review Authority (approval number 2021 - 01642) and the Swedish Medical Products Agency (EudraCT-number 2021-001059-15). Trial registration date 16th February 2022.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"16 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13396309/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148561017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimization of imaging parameters for Yttrium-90 bremsstrahlung emission computed tomography after selective internal radiotherapy.","authors":"Xin Xie, Qi Wang, Yuemin Zhang, Hui Xu, Lulu Yang, Aimin Yang, Xin Zheng, Huasi Hu, Jianjun Xue","doi":"10.1186/s13550-026-01478-w","DOIUrl":"10.1186/s13550-026-01478-w","url":null,"abstract":"<p><strong>Background: </strong>Yttrium-90 labeled microspheres based selective internal radiotherapy (⁹⁰Y-SIRT) is an established local-regional therapy for unresectable hepatocellular carcinoma (HCC) which demonstrating significant survival improvements in multiple clinical trials. Post therapeutic ⁹⁰Y imaging is essential for in vivo ⁹⁰Y microspheres biodistribution evaluation and absorbed dose estimation. We aim to study the effects of ⁹⁰Y bremsstrahlung imaging parameters including energy window center, width and acquisition time on the quality of ⁹⁰Y SPECT/CT to provide optimal imaging conditions after ⁹⁰Y-SIRT.</p><p><strong>Results: </strong>Using the NEMA IEC NU2 body phantom and Siemens Symbia™ T16 SPECT/CT scanner equipped with a high-energy general-purpose collimator (HEGPC), seven energy window settings and two acquisition times (20s / frame and 40s / frame) were investigated and analyzed. ⁹⁰Y bremsstrahlung imaging with 94 keV ± 40% energy window limits and 20s / frame acquisition time demonstrated the highest contrast-to-noise ratio (CNR) and contrast recovery coefficient (Q_H). In further analysis using a single hot sphere (diameter = 22 mm), the imaging parameter combination of 94 keV ± 40% and 20s / frame showed the lowest coefficient of variation (COV), while the residual count error in the lung insert ([Formula: see text]) remained at a relative low level among all imaging parameters.</p><p><strong>Conclusions: </strong>For HEGPC, 94 keV ± 40% with 20s / frame is the optimal acquisition parameter for ⁹⁰Y BECT imaging, while 80 keV ± 30% is also good energy window center and widths.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13661875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148520225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preclinical evaluation of [¹⁸F]fluoroethylresorufin as PET tracer for cerebral amyloid angiopathy.","authors":"Daniel Bleher, Marilena Poxleitner, Ann-Kathrin Grotegerd, Oliver Hihn, Laura Kuebler, Gregory Bowden, Martin Schaller, Florian C Maier, Bettina Weigelin, Bernd J Pichler, Andreas Maurer, Kristina Herfert","doi":"10.1186/s13550-026-01470-4","DOIUrl":"10.1186/s13550-026-01470-4","url":null,"abstract":"<p><strong>Background: </strong>Cerebral amyloid angiopathy (CAA) is characterized by the accumulation of β-amyloid (Aβ) in cerebral vessel walls, predominantly Aβ_1-40, and frequently co-occurs with Alzheimer's disease (AD). Reliable in vivo discrimination between vascular and parenchymal Aβ deposits (PEA) in AD is crucial for the assessment of CAA-related risks in anti-Aβ immunotherapies. Current Aβ PET tracers lack the ability to distinguish between vascular and parenchymal Aβ. The phenoxazine derivatives resorufin and ethyl-resorufin were previously shown to bind preferably to CAA over PEA. We therefore evaluated the fluorine-18-labeled resorufin derivative, [¹⁸F]fluoroethylresorufin ([¹⁸F]FER) as a potential PET tracer for selective in vivo detection of vascular Aβ.</p><p><strong>Results: </strong>The binding specificity of [³H]FER was assessed using recombinant Aβ_1-40 and Aβ_1-42 fibrils as well as in vitro autoradiography on mouse brain tissue of APP23 (CAA+/PEA+) and APPPS1 (CAA-/PEA+) models, and compared to those of [³H]PIB. [¹⁸F]FER and its deuterated analog were synthesized for evaluation of brain pharmacokinetics, metabolism, and in vivo binding using PET imaging in wild-type, APPPS1, and APP23 mice. [³H]FER bound with higher affinity to Aβ_1-40 (K_d = 9.4 nM) than to Aβ_1-42 (K_d = 89.1 nM), consistent with its intended CAA selectivity. Autoradiography revealed preferential labeling of vascular amyloid in APP23 mice, with minimal binding in APPPS1 and wild-type tissue. In vivo, [¹⁸F]FER exhibited high brain uptake (peak SUV = 1.5) and rapid clearance, but metabolic degradation was fast, with ~ 45% parent fraction remaining in the brain at 15 min. Deuteration did not improve stability but did improve washout kinetics. PET imaging with (d₄)-[¹⁸F]FER demonstrated a cortical uptake pattern similar to [¹¹C]PIB, indicating non-selective binding in vivo.</p><p><strong>Conclusions: </strong>[¹⁸F]FER showed promising in vitro affinity for vascular amyloid but lacked in vivo selectivity, likely due to rapid metabolism and high lipophilicity. These findings highlight the challenges of achieving in vivo CAA specificity and provide guidance for the optimization of future tracers targeting vascular Aβ pathology.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13385527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148454779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sarcopenia does not affect total liver function measured using technetium-99m mebrofenin hepatobiliary scintigraphy.","authors":"Pieter Arntz, Pim Olthof, Fadi Rassam, Roelof Bennink, Robert-Jan Coelen, Thomas van Gulik, Jan Heil, Geert Kazemier, Bart Takkenberg, Joris Erdmann","doi":"10.1186/s13550-025-01355-y","DOIUrl":"10.1186/s13550-025-01355-y","url":null,"abstract":"<p><strong>Background: </strong>Hepatobiliary scintigraphy (HBS) using technetium-99m mebrofenin is used to preoperatively estimate risk of adverse outcomes after major liver resections. Sarcopenia has been independently associated with adverse outcomes after surgery. This retrospective cohort study aimed to correlate patient- and disease-related factors, including sarcopenia, with total liver function (TLF) through HBS analysis.</p><p><strong>Results: </strong>During the study period, 346 patients underwent HBS to quantify TLF. The median TLF was 15.0 (12.1-16.7) %/min. Body composition parameters were not correlated to TLF. Older age, a diagnosis of hepatocellular carcinoma, underlying cirrhosis and high serum bilirubin levels were independently correlated with decreased TLF. In contrast, the absence of underlying liver disease and overall good health were independently correlated with higher TLF. Sarcopenia was not correlated with TLF.</p><p><strong>Conclusion: </strong>Sarcopenia does not impact TLF. Total liver function measured with HBS is negatively correlated with older age, a diagnosis of hepatocellular carcinoma, underlying cirrhosis and serum bilirubin level.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13421617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148430164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of [18F]MFPBG: a novel automatically radiolabeled probe for NET PET imaging.","authors":"Zhenheng Wei, Guojian Zhang, Xinai Wu, Jie Li, Pengfei Xia, Xuemei Wang","doi":"10.1186/s13550-026-01482-0","DOIUrl":"10.1186/s13550-026-01482-0","url":null,"abstract":"<p><strong>Background: </strong>Cardiac sympathetic nerve imaging is critical for sudden death risk stratification in heart failure patients. Conventional SPECT probe [¹²³I]MIBG is limited by inadequate spatial resolution and restricted quantitative ability. While [¹⁸F]-labeled PET probes have shown promise, some suffer from high hepatic uptake that interferes with cardiac signals, and low radiolabeling efficiency hinders clinical translation. Thus, a novel norepinephrine transporter (NET) probe [¹⁸F]MFPBG was developed for cardiac sympathetic nerve imaging, synthesized via an automated radiolabeling module.</p><p><strong>Results: </strong>The decay-corrected radiochemical yield of [¹⁸F]MFPBG was 15.14±2.57% (n = 5), with a retention time of 11.87 minutes. The probe exhibited a radiochemical purity of >95% and remained stable (purity >95%) for 4 hours at ambient temperature. The biodistribution studies in ICR mice (n=28) showed a cardiac uptake of 9.34±0.73 %ID/g at 5 minutes post-injection, with the heart to liver ratio (3.99±0.15). At 120 minutes, cardiac uptake remained high (4.88±0.85 %ID/g), and the heart to liver ratio was 4.46±0.85. In Bama miniature pigs, imipramine pre-treatment significantly reduced cardiac uptake compared to controls at 10 minutes (SUV-bw: 2.08±0.16 vs. 3.73±0.29; P < 0.001) and 60 minutes (SUV-bw: 1.21±0.14 vs. 2.15±0.21; P < 0.001).</p><p><strong>Conclusions: </strong>[¹⁸F]MFPBG demonstrates NET-mediated uptake, stable cardiac retention, low background noise, and suitability for automated radiolabeling, establishing it as a promising agent for cardiac sympathetic nerve imaging with favorable characteristics that warrant further preclinical validation, including in vivo metabolic profiling, to fully assess its clinical translatability.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13627521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148404045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radioluminescence microscopy of tumor organoids enabled by a reconfigurable high-resolution imaging setup.","authors":"Sofia Demianova, Martin Dierolf, Maximilian Reichert, Laura Schmidleitner, Franz Pfeiffer, Wolfgang A Weber","doi":"10.1186/s13550-026-01484-y","DOIUrl":"10.1186/s13550-026-01484-y","url":null,"abstract":"<p><strong>Background: </strong>This study aims to construct and implement an experimental radioluminescence microscopy (RLM) setup using a standard light microscope to visualize tumor organoids with high resolution. This approach seeks to address the challenges of imaging organoids, facilitating advancements in precision medicine for cancer research. Tumor organoids grown in collagen were incubated with 100 MBq to 120 MBq of 18F-fluorodeoxyglucose to visualize metabolic activity within their structures. Imaging was performed using a sensitive electron-multiplying charge-coupled device in conjunction with a scintillator crystal and an optical system with a high light collection efficiency and adapted magnification.</p><p><strong>Results: </strong>The constructed RLM setup demonstrated high-resolution imaging of organoid samples, significantly exceeding the resolution achievable with positron-emission tomography. The combination of RLM with brightfield and fluorescence microscopy provided comprehensive morphologic and metabolic characterization of the organoids at sub-organoid spatial resolution.</p><p><strong>Conclusion: </strong>The study successfully illustrates the feasibility of using a modified light microscope for RLM to achieve imaging of tumor cell metabolism in organoids with a spatial resolution on the order of tens of micrometers. This approach opens new avenues for studies of tumor cell metabolism during tumor progression and during therapeutic interventions.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"16 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13346395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148403996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a pulmonary embolism quantification method using single photon emission computed tomography ventilation and perfusion scintigraphy.","authors":"Harini Fernando, Christopher Sibley-Allen, Charlotte Fowler, Livieratos Lefteris","doi":"10.1186/s13550-026-01379-y","DOIUrl":"10.1186/s13550-026-01379-y","url":null,"abstract":"<p><strong>Background: </strong>Pulmonary embolism (PE) remains an important cause of cardiovascular death and morbidity worldwide. Conventionally, PE imaging is reported in a binary manner, with reports stating the presence or absence of a thrombus. No generally accepted graduated quantification systems are available to guide management or predict the development of acute or long-term complications. V/Q SPECT is a well-established method for diagnosing PE in acute and chronic settings. The use of volumetric perfusion and ventilation functional images could potentially calculate the volumetric PE burden. This project aimed to develop and optimise a volumetric V/Q SPECT PE quantification technique, utilising V/Q SPECT phantoms, 100 consecutive clinical V/Q SPECT studies, and advanced V/Q SPECT image analysis with semiautomated %PE quantification methods.</p><p><strong>Results: </strong>Lung phantoms with PE defects of known volume demonstrated that the choice of acquisition, reconstruction parameters, and the volumetric cutoff threshold influences %PE results. The V/Q quotient image utilised a semiautomated technique with phantom-derived optimisation parameters, which was found to be the most accurate quantification method.</p><p><strong>Conclusion: </strong>This study, combining phantom and clinical study analysis, developed a successful method for semiautomated V/Q SPECT %PE quantification, which has the potential utility of guiding patient management and outcome prediction.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13627622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148396305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying genetics biomarkers in correlation with pathological and PSMA PET/CT characteristics in prostate cancer.","authors":"Lili Qu, Kaiyue Li, Muwen Wang, Yadi Xiao, Xin Jin, Hang Zhou, Lujie Yuan, Yuekai Li, Shiwei Wang, Rui Li, Marcus Hacker, Xin Li, Xiang Li","doi":"10.1186/s13550-026-01471-3","DOIUrl":"10.1186/s13550-026-01471-3","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer is a prevalent disease with diverse tumor characteristics that complicate treatment. The integration of spatial patterns from prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT), pathology and expanding genomic data represents a groundbreaking advancement in histo-imaging genomics. The aim of this study was to elucidate the internetwork mapping between genetic biomarkers and PSMA PET/CT imaging in prostate cancer patients.</p><p><strong>Results: </strong>mRNA sequencing and clinical data from 433 prostate cancer patients were retrieved from The Cancer Genome Atlas (TCGA) database. Differential gene expression between the Gleason score (GS) > 7 and GS ≤ 7 groups was analyzed. Feature selection was performed following the univariate and multivariate logistic regression analyses. A GS predictive model was developed using multivariate logistic regression. Additionally, local samples and images from 27 patients were collected. PSMA PET/CT imaging was performed before radical prostatectomy, and mRNA sequencing of prostate cancer lesions was conducted using next-generation sequencing. Differentially expressed genes identified from the TCGA dataset were subsequently analyzed for correlations with PET-related metrics in the local dataset by utilizing Pearson correlation analysis.Out of the TCGA dataset, 174 genes exhibited differential expression. After feature selection, 53 genes remained. In the local dataset, ten genes (EFNA2, CACNA1I, CA1, MYBPC3, CYP1A1, TLCD3B, LRTM2, GBX2, SPSB4, and GDF3) demonstrated significant associations with PET-related metrics. When comparing the differential expression of genes between the GS>7 and GS≤7 groups, six genes (STMN2, CYP1A1, THRSP, LIPC, GBX2, and SPSB4) in the GS>7 group and eight genes (FBXL16, KLK14, DIRAS2, TERB2, PRAME, UTS2B, UGT2B15, and LINC02798) in the GS≤7 group were significantly correlated with PET-related parameters.</p><p><strong>Conclusions: </strong>This study identified genetic markers significantly correlated with PSMA PET/CT imaging features in prostate cancer patients. These findings may provide a valuable foundation for optimizing prostate cancer diagnostic procedures and tailoring therapeutic approaches based on genetic and imaging biomarkers.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13612772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148387194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}